MOST NOTEWORTHY: This morning's noteworthy initiations included Nokia Corp (NOK), Fortune Brands, Inc (FO), Whirlpool Corp (WHR), Dick's Sporting Goods, Inc (DKS), Kona Grill, Inc (KONA):

• JP Morgan started Nokia Corp (NYSE: NOK) with an Overweight rating, believing the handset market is strong and expects gross profits to rise in 2007.

• Soleil wants to wait on the sidelines of Fortune Brands Inc (NYSE: FO), initiating shares with a Neutral rating, given the potential acquisition of Sweden's V&S Group along with the softness in the home and hardware segment.

• Soleil also started Whirlpool Corp (NYSE: WHR) with a Hold rating based on valuation, which they believe reflects the company's outlook through 2009.

• Nollenberger expects Dick's Sporting Goods (NYSE: DKS) will continue to outperform its peers, starting shares off with a Buy rating, and believes the recent pullback provides a compelling buying opportunity.

• KeyBanc is positive on Kona Grill's (NASDAQ: KONA) differentiated brand, compelling unit economics, positive SSS opportunity and growth, starting shares with a Buy rating...

OTHER INITIATIONS:

• Ceva, Inc (NASDAQ: CEVA) was initiated at CIBC with a Sector Outperform rating.

• Black & Decker Corp (NYSE: BDK) and Briggs & Stratton Corp (BGG) were initiated with Hold ratings at Soleil.

• La Jolla Pharmaceutical Co (NASDAQ: LJPC) was started with a Sell rating at Lazard.

• Aviza Technology, Inc (NASDAQ: AVZA) was initiated with a Hold rating at Needham.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

MOST NOTEWORTHY: The pharmacy benefit managers sector, financials E*Trade Financial Corp (ETFC) and TD Ameritrade Holding Corp (AMTD) and transports J.B. Hunt Transport Services (JBHT) and Knight Transportation (KNX) were today's most noteworthy initiations:

• CIBC is positive on the pharmacy benefit managers group given increasing generic utilization, continued growth in specialty pharmacy, improving mail-order penetration and share repurchases. CIBC initiated Express Scripts, Inc (NASDAQ: ESRX) with a Sector Outperformer and $104 target as the firm expects continued strong performance as the company benefits from positive secular industry trends, and initiated Medco Health Solutions (NYSE: MHS) with a Sector Performer and $82 target on valuation.
• BMO capital started E*Trade Financial Corp (NASDAQ: ETFC) and TD Ameritrade Holdings Corp (NASDAQ: AMTD) with Outperform ratings.
• Cathay Financial started J.B. Hunt Transport (NASDAQ: JBHT) and Knight Transportation (NYSE: KNX) with Neutral ratings.

OTHER INITIATIONS:

• BMO started Charles Schwab Corp (NASDAQ: SCHW) with a Market Perform rating
• Citigroup started NYSE Euronext (NYSE: NYX) with a Buy rating and $113 target.
• AG Edwards initiated shares of La Jolla Pharmaceutical Co (NASDAQ: LJPC) with a Buy rating and $11 price objective.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

There's a very interesting feature over at The Motley Fool and I find it very useful . The CAPS community stock rating pages give highly understandable insight plus gems of investor feedback which help to bring the knowledge about individual stocks to a layman's level. Investment players like me benefit from this feature.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) has the CAPS number one spot this weekend based on a 43.1% stock value spike fueled by moderately positive interim results in a phase III study of its number one product Riquent. The drug in question shows promise in the treatment of Lupus, a chronic inflammatory disease that can cause organ malfunction. However, analysts are skeptical regarding the value of this phase III test result as a basis for developing a strong position in the company.

Even those investors who express a positive mood, unwittingly show reservations about whether or not the LJPC spike can be supported. Analyst consensus is "hold" on LJPC stock and neutral on the company. It is worthy of note that an Associated Press news release regarding the LJPC test results states: "Several drug makers are in advanced stage trials for lupus drugs. To date, no specific lupus drug has been approved in the United States."(emphasis mine)

I myself expect LJPC share value to recede quickly and I would base my choices on that belief. I see nothing else of interest in the company's fundamentals... at least not to the positive side. If I had shares of JLPC which I purchased at bargain, I'd be tempted to unload half of them immediately to reap some of the current gain. If I had bought those shares for a higher price, I'd be comfortable holding on to them for a while just to see what develops.